Myriad Adds to Melanoma Franchise with New Gene Expression Test Acquisition

Under the terms of the deal, Myriad will have commercialization rights to "all tests derived from the technology on a worldwide basis in exchange for upfront fees and contingent payments based upon the commercial success of the products."

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.